FDA Rejects Disc Medicine's Porphyria Drug Over Uncertain Biomarker Benefit
TL;DR
The FDA rejected Disc Medicine's bitopertin for porphyria, citing uncertainties that the biomarker used as the efficacy endpoint may not translate to real patient benefit, marking the first setback for a drug in Commissioner Makary's fast-track review program and sending Disc's shares lower.
- FDA rejects rare disease therapy from Disc Medicine, early recipient of commissioner’s voucher statnews.com
- FDA rejects Disc's rare disease drug despite commissioner's voucher Fierce Biotech
- Drug For Rare Genetic Disorder Goes From FDA Priority to Reject in Four Months Bloomberg.com
- Disc Medicine (IRON) Shares Plunge by 39% to $43.99 GuruFocus
- FDA issues complete response letter for Disc Medicine’s EPP drug Investing.com Nigeria
Want the full story? Read the original reporting
Read on statnews.com